Insulin resistance contributes to the pathophysiology of diabetes and is a hallmark of obesity, metabolic syndrome, and many cardiovascular diseases. Therefore, quantifying insulin sensitivity/resistance in humans and animal models is of great importance for epidemiological studies, clinical and basic science investigations, and for eventual use in clinical practice. Direct and indirect methods of varying complexity are currently employed for these purposes. Some methods rely on steady-state analysis of glucose and insulin while others rely on dynamic testing. Each of these methods has distinct advantages and limitations. Thus, optimal choice and employment of a specific method depends on the nature of the studies being performed. or after an oral glucose load (dynamic). In particular, the quantitative insulin-sensitivity check index (QUICKI) has been extensively validated against the reference standard glucose clamp method. QUICKI is a simple, robust, accurate, reproducible method that appropriately predicts changes in insulin sensitivity after therapeutic interventions as well as the onset of diabetes. In this Frontiers article, we highlight merits, limitations, and appropriate use of current in vivo measures of insulin sensitivity/resistance.
INTRODUCTION
Insulin is an essential peptide hormone whose metabolic actions maintains whole body glucose homeostasis and promote efficient glucose utilization (4) . Insulin stimulates increased glucose disposal in skeletal muscle and adipose tissue while inhibiting gluconeogenesis in liver to help regulate glucose homeostasis. In addition to these classical insulin target tissues, there are many other important physiological targets of insulin including the brain, pancreatic beta cells, heart, and vascular endothelium that help to coordinate and couple metabolic and cardiovascular homeostasis under healthy conditions (4, 54, 72, 79) . Insulin has concentrationdependent saturable actions to increase whole-body glucose disposal. The maximal effect of insulin defines "insulin responsiveness" while the insulin concentration required for a halfmaximal response defines "insulin sensitivity" (Fig. 1A ).
Insulin resistance is typically defined as decreased sensitivity or responsiveness to metabolic actions of insulin such as insulin-mediated glucose disposal and inhibition of hepatic glucose production (HGP). The concept of insulin resistance was proposed as early as 1936 to describe diabetic patients requiring high doses of insulin (52) . Insulin resistance plays a major sensitivity depends on achieving steady-state conditions. It is often assumed that data from an arbitrary time point at the end of the clamp study (e.g., 2 h) represents steady-state values.
However, defining "steady-state" as a period greater than 30-min (at least 1 h after initiation of insulin infusion) during which the coefficient of variation for blood glucose, plasma insulin, and glucose infusion rate are less than 5% is a more rigorous approach that may determine more accurate values for M and SI Clamp (22, 56) .
Another important assumption of the glucose clamp method is that HGP is completely suppressed by steady-state hyperinsulinemia. For subjects with normal insulin sensitivity, this may be achieved with an insulin infusion rate in the range of 40 -60 mU/m 2 /min (16, 87) .
However, there may be incomplete suppression of hepatic glucose production at lower insulin infusion rates or in insulin resistant populations. To address this issue, it is possible to use radiolabeled glucose tracers under clamp conditions to estimate HGP so that appropriate corrections can be made to M (38, 68, 85, 87) . An alternative approach is to choose an insulin infusion rate that is sufficiently high to completely suppress HGP according to the insulin sensitivity/resistance of the population to be studied.
A critical consideration for interpretation of glucose clamp data is that M is routinely obtained at only a single insulin infusion rate. The choice of this rate determines a level of hyperinsulinemia that is roughly comparable among all subjects studied. Comparisons between M or SI Clamp among different subjects is valid only if the same insulin infusion rate is used for all subjects. Importantly, the use of a single insulin infusion rate for comparisons of insulin sensitivity/resistance assumes that the steady-state insulin level achieved is in the range where M can vary according to differences in insulin sensitivity. If the insulin infusion rate is not appropriately matched to the insulin sensitivity/resistance of the population being studied it is possible that erroneous conclusions may be drawn. For example, in an insulin resistant population, a higher insulin infusion rate is required to avoid missing potential differences in insulin sensitivities among subjects (Fig. 1B , curve c). Similarly, for an insulin-sensitive population, a lower insulin infusion rate is more appropriate (Fig. 1B , curve a). To address these issues, the ideal approach is to generate a full insulin dose-response curve by performing the glucose clamp procedure at multiple insulin infusion rates in a stepwise fashion (16, 87) .
However, this is rarely done since feasibility issues arising from this more complete approach are daunting even in sophisticated research settings.
When subjects are non-diabetic, their fasting glucose level is within the normal range. Some investigators will clamp blood glucose at fasting levels (isoglycemic) while others will clamp blood glucose at an arbitrary pre-determined level of glycemia within the normal range (euglycemic). In the case of diabetic subjects, the difference between euglycemia and isoglycemia may be large. There are pros and cons to choosing either approach for diabetic subjects and non-diabetic subjects. The rationale for performing isoglycemic clamps in diabetic subjects is that large acute changes in glycemia may alter insulin sensitivity. For diabetic subjects under isoglycemic conditions, it may be necessary to correct M for urinary losses of glucose. In addition, even in non-diabetic subjects there is variability in fasting glucose levels.
Thus, for isoglycemic clamps, SI Clamp is more appropriate to use than M because SI Clamp normalizes for differences in fasting glucose levels (as well as for differences between fasting and steady-state clamp insulin levels). With euglycemic clamps in non-diabetic subjects either M or SI Clamp are appropriate to use (although M does not correct for differences between fasting and steady-state clamp insulin levels).
Differences between arterial and venous blood glucose increase in proportion to insulin sensitivity and dose. Therefore, adjusting glucose infusion rates based on venous sampling of glucose may lead to overestimation of insulin sensitivity. To minimize this issue, the hand used for blood sampling may be cannulated in retrograde fashion and warmed with a heating pad (opening arterio-venous anastomoses) to "arterialize" the venous blood (71) .
Computer based algorithms have been developed to help control the GIR in response to frequently measured blood glucose levels (33, 41). However, efficient regulation of GIR may be empirically achieved with an experienced proficient operator
Advantages and Appropriate Usage -The main advantage of using the glucose clamp to estimate insulin sensitivity/resistance in humans is that it directly measures whole body glucose disposal at a given level of insulinemia under steady-state conditions. Conceptually, the approach is straightforward and there are a limited number of assumptions which are clearly defined. In addition, the glucose clamp has excellent test characteristics. For example, M typically has a coefficient of variation of 0.10 and a discriminant ratio of ~6 (a measure of both reproducibility and the ability to distinguish individual results) (65) . When radio-labeled glucose tracers are used under clamp conditions it is possible to simultaneously quantify HGP and whole body glucose disposal (18, 87) . Under these conditions, one can study and distinguish hepatic and peripheral (predominantly skeletal muscle) insulin sensitivity/resistance. Similarly, radiolabeled tracers of glycerol or amino acids may be used during the glucose clamp to assess insulin sensitivity with respect to lipolysis or protein metabolism (42, 44) . In addition, 31 P magnetic resonance spectroscopy (MRS) may be used in conjunction with the glucose clamp to assess rates of insulin-stimulated muscle mitochondrial ATP synthase flux and insulin-stimulated increases in concentrations of intra-myocellular inorganic phosphate (P i ) (75) . Doppler and contrast ultrasound imaging have also been used in conjunction with the clamp to study insulin sensitivity with respect to vascular actions of insulin (24) . In research settings where assessing insulin sensitivity/resistance is of primary interest and feasibility is not an issue (e.g., study Assumptions and Considerations -As with the glucose clamp, the validity of the IST depends on achieving steady-state conditions. However, this is not routinely verified.
Moreover, it is assumed that combined effects of hyperinsulinemia, hyperglycemia, and hypoglucagonemia during the IST are sufficient to completely suppress HGP. It is also assumed that the somatostatin infusion is sufficient to completely suppress endogenous insulin and glucagon secretion. The same insulin infusion rate is universally applied in the IST. However, this rate may not be ideal for every population being studied. Thus, for the IST, issues regarding erroneous determinations of insulin sensitivity/resistance in populations with different degrees of insulin resistance are similar to those described above for the glucose clamp. Another consideration is that the insulin infusion rate universally applied in the IST does not result in the same SSPI for all subjects (due to differences in insulin clearance, volume of distribution, etc.).
Since SSPG is not corrected for SSPI, this may introduce some error. distribution of the glucose bolus in a monocompartmental space is assumed to occur. Second, glucose disappearance in response to glucose and/or insulin is assumed to occur at a monoexponential rate. Third, the glucose concentration at the end of the FSIVGTT is assumed to be identical to the beginning concentration. Fourth, insulin is assumed to act from a "remote compartment" (extravascular) to promote glucose disappearance. This "remote compartment" may represent an interstitial or extracellular space where insulin directly exerts its metabolic actions (11) . Fifth, the mimimal model lumps together effects of insulin to promote glucose disposal in skeletal muscle and suppress HGP. Finally, to obtain a valid estimate of S I the minimal model assumes that total insulin secretion (endogenous plus exogenous) during the FSIVGTT is above a certain threshold (101) .
Advantages and Appropriate Usage
In addition to S I , other minimal model parameters may be used to estimate a "glucose effectiveness" index (S G ). S G is defined as the ability of glucose per se to promote its own disposal and inhibit HGP in the absence of an incremental insulin effect (i.e., when insulin is at basal levels). The minimal model was originally developed in dogs that have a delayed insulin secretory response to the FSIVGTT when compared with humans (14) . By contrast, in humans, the peak insulin secretion induced by the FSIVGTT temporally overlaps with the period in which high glucose concentrations are the primary determinant of glucose disappearance. Therefore, to increase the accuracy of both S I and S G in humans, a modified FSIVGTT was developed where exogenous insulin (or tolbutamide) is given at a time where glucose levels have decreased to near normal levels. This allows the minimal model to more effectively distinguish between glucose effectiveness and insulin sensitivity (15, 101) . Finally, because the FSIVGTT is a dynamic test, information about beta cell function can also be derived from minimal model analysis (11, 13, 46) . Alternatively, it is possible to use a Bayesian approach (using prior knowledge during model identification routines) with addition of a non-accessible compartment to the original "cold" model (26) . The relative merits and limitations of individual surrogate indexes are discussed below.

1/(Fasting Insulin) -
In healthy subjects, elevations in fasting insulin levels (with normal fasting glucose levels) correspond to increased insulin resistance. Indeed, in nondiabetic subjects, 1/(fasting insulin) is a well known proxy for insulin sensitivity that decreases as subjects become more insulin resistant (and fasting insulin levels rise) (59). However, insulin concentrations are not normally distributed. Thus, linear correlations between 1/fasting insulin and estimates of insulin sensitivity from the glucose clamp are not that strong. In addition, this index does not take into account the inappropriately low insulin secretion in the face of hyperglycemia seen in diabetic subjects or glucose intolerant subjects. Consequently, using 1/(fasting insulin) as a measure of insulin sensitivity/resistance in patients with glucose intolerance or type 2 diabetes who have diminished pancreatic reserve leads to erroneous results.
Glucose/Insulin Ratio (G/I ratio) -
A number of studies have used the fasting G/I ratio as an index of insulin resistance (particularly in patients with polycystic ovarian syndrome) (60, 91, 98) . In the case of non-diabetic subjects, the G/I ratio is essentially functionally equivalent to 1/insulin since fasting glucose levels are all in the normal range. However, the G/I ratio does not appropriately reflect the physiology underlying the determinants of insulin sensitivity (80) . For example, given the same level of relative fasting hyperinsulinemia in a diabetic and a nondiabetic insulin-resistant subject, 1/(fasting insulin) remains unchanged. However, under these same conditions, the G/I ratio paradoxically and erroneously increases in the diabetic subject.
Therefore, the fasting G/I ratio is a conceptually flawed index of insulin sensitivity. 
Surrogates Derived from Dynamic Tests
Procedure and Concept -Surrogate indexes of insulin sensitivity have been developed that use information derived from dynamic tests including OGTT, meal tolerance tests, and IVGTT.
Procedures for these tests have been described in a previous section. Specific indexes including Assumptions and Considerations -The oral route of glucose delivery is more physiological than intravenous glucose infusion. However, poor reproducibility of the OGTT and meal tolerance test due to variable glucose absorbtion, splanchnic glucose uptake, and additional incretin effects need to be considered. Thus, distinguishing direct metabolic actions of insulin following oral ingestion of glucose or a mixed meal is more problematic than after FSIVGTT. In addition, as with many other measures of insulin sensitivity, surrogates derived from dynamic testing generally incorporate both peripheral and hepatic insulin sensitivity. Although OGTT involves considerably less work than FSIVGTT, dynamic testing in general requires more effort and cost than fasting blood sampling.
General Advantages and Appropriate Usage -Many surrogate measures derived from dynamic data correlate reasonably well with glucose clamp estimates of insulin sensitivity (45, 63, 66) . Estimates of insulin sensitivity derived from OGTT predict the development of type 2 diabetes in epidemiologic studies (3, 48, 49) . Furthermore, insulin sensitivity, (SI oral ) estimated from minimal model analysis of OGTT or meal tolerance tests correlates well with glucose clamp measures (27, 31). The advantage of surrogates based on dynamic testing is that information about insulin secretion can be obtained at the same time as information about insulin action. However, if one is only interested in estimating insulin sensitivity/resistance, fasting surrogates may be preferable to dynamic surrogates because they are simpler to obtain.
Insulin Sensitivity Index-Matsuda (ISI (Matsuda) ) -Originally proposed by Matsuda and
DeFronzo (66), this is an insulin sensitivity index that reflects a composite estimate of hepatic and muscle insulin sensitivity determined from OGTT data. ISI (Matsuda) 
ASSESSING INSULIN SENSITIVITY/RESISTANCE IN ANIMALS
Animal models of insulin resistance are helpful for understanding pathophysiology and for developing and evaluating therapeutic agents used for treatment and/or prevention of insulin resistance and its associated diseases. As in humans, the hyperinsulinemic euglycemic clamp is considered the reference standard for measuring insulin sensitivity in animals (7). In addition, various dynamic tests including IVGTT, OGTT, and intra-peritoneal insulin tolerance test (ITT) have been used (23, 34, 73) . Several studies also use surrogates derived from fasting conditions, such as fasting insulin levels, HOMA-IR, and QUICKI (51, 62, 78) .
Hyperinsulinemic Euglycemic Glucose Clamp
Procedure and Concept -Conceptually, the glucose clamp in animals is the same as in Limitations and Considerations -Regarding the glucose clamp in animals, additional considerations are needed while conducting and interpreting these studies, especially for rodents (7) . Unlike humans, rodents have no true physiological fasting state. Imposing a nonphysiological fasting period leads to significant decrease in body weight, depletion of hepatic glycogen content, and improved insulin sensitivity. Therefore, under these non-physiological fasting conditions, plasma glucose and insulin levels may not attain steady-state conditions.
Furthermore, it is likely that the glucose clamp technique in rodents is not as accurate and reliable as in humans. Rodents have very small blood volumes (~2 ml in mice). Therefore, limited sampling ability makes it difficult to achieve and rigorously verify steady-state clamp conditions (especially with respect to insulin levels). In addition, the glucose clamp is stressful in mice (even if done under anesthetized conditions).
Advantages and Appropriate Usage -The glucose clamp can be used to measure tissuespecific insulin action and glucose metabolism such as: 1) basal and insulin-stimulated HGP, 2)
insulin-stimulated whole body glucose uptake, glycolysis, and glycogen synthesis, and 3)
insulin-stimulated glucose uptake, glycolysis, and glycogen synthesis in individual tissues (e.g., skeletal muscle, adipose tissue, and heart) (58). Additionally, biochemical/molecular assays may be performed to assess tissue-specific insulin signaling activities and tissue-specific triglyceride contents (57) . When assessing insulin sensitivity is a primary objective and feasibility is not an issue, the glucose clamp study is the method of choice in animals. These tests are frequently used to assess glucose tolerance and insulin sensitivity in mouse models of diabetes or insulin resistance with isolated and specific genetic changes.
Glucose and Insulin Tolerance Tests
Advantages, Limitations, and Appropriate Usage -Insulin tolerance tests (ITTs) and glucose tolerance tests (GTTs) can be conducted with more ease than the glucose clamp. However, unlike the clamp, these methods do not provide precise estimates of insulin sensitivity or tissuespecific glucose disposal. IPGTT has an advantage over OGTT in that it excludes incretin effects. In the case of ITT, the possibility of hypoglycemia and ensuing counter-regulatory homeostatic mechanisms have the potential to confound estimates of insulin sensitivity. All of these tests can be stressful to the animals. In addition, as discussed before, imposing a non- Minimal model uniquely identifies model parameters that determine a best fit to glucose disappearance during the modified FSIVGTT. S I : fractional glucose disappearance per insulin concentration unit; S G (glucose effectiveness): ability of glucose per se to promote its own disposal and inhibit HGP in the absence of an incremental insulin effect (i.e., when insulin is at basal levels). conditions. GIR is plotted as a function of insulin infusion rate. In typical clamp studies, a single insulin infusion rate is used for all subjects. In an insulin-sensitive population (curve a), a lower insulin infusion rate is more appropriate. A clamp study using a single high insulin infusion rate may fail to detect changes in insulin sensitivity in this population. Likewise, a higher insulin infusion rate is required to avoid missing potential differences in insulin sensitivities among insulin resistant subjects (curve c). Differential equations describing glucose dynamics (G(t)) in a monocompartmental "glucose space" and insulin dynamics in a "remote compartment" (X(t)) are shown at the top. Glucose leaves or enters its space at a rate proportional to the difference between plasma glucose level, G(t) and the basal fasting level, G b . In addition, glucose also disappears from its compartment at a rate proportional to insulin levels in the "remote" compartment (X(t)). In this model, t = time;
Simple Surrogate Indexes
G(t) = plasma glucose at time t; I(t) = plasma insulin concentration at time t; X(t) = insulin 
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